Pfizer Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7170811035
USD
25.70
0.13 (0.51%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pfizer Inc. stock-summary
stock-summary
Pfizer Inc.
Pharmaceuticals & Biotechnology
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Company Coordinates stock-summary
Company Details
235 E 42ND ST , NEW YORK NY : 10017-5703
stock-summary
Tel: 1 212 5732323
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 264 Schemes (28.78%)

Foreign Institutions

Held by 651 Foreign Institutions (15.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Albert Bourla
Chairman of the Board, Chief Executive Officer
Mr. Shantanu Narayen
Lead Independent Director
Dr. Susan Desmond-Hellmann
Director
Mr. Ronald Blaylock
Independent Director
Mr. Joseph Echevarria
Independent Director
Dr. Scott Gottlieb
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
14,653 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,903 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 235,718 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

409.58%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

18.34%

stock-summary
Price to Book

2.66